XOMAPHIGH SIGNALFINANCIAL10-K

XOMAP executed a dramatic financial turnaround with net income swinging from -$13.8M to +$31.7M (+329%) while significantly increasing share buybacks to $16M and nearly doubling revenue to $52.1M.

This represents a remarkable transformation from loss-making to highly profitable operations, suggesting either a major business model shift or successful execution of their royalty acquisition strategy. The substantial increase in share buybacks indicates management's confidence in the business trajectory and commitment to returning capital to shareholders.

Comparing 2026-03-18 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

XOMAP delivered exceptional financial performance with revenue growing 83% to $52.1M and a stunning $45.5M improvement in net income to achieve $31.7M in profits. Operating cash flow turned strongly positive at $2.9M while the company aggressively returned capital through $16M in share buybacks, though cash reserves declined 18% to $82.9M. The overall picture signals a successful transformation into a profitable, cash-generating business with management actively optimizing capital allocation, though the increase in current liabilities and asset base suggests ongoing business expansion or acquisition activity.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+123307.7%
$13K→$16.0M

Share repurchases increased 123307.7% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+329.4%
-$13.8M→$31.7M

Net income grew 329.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+128.5%
-$40.0M→$11.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+120.9%
-$13.7M→$2.9M

Operating cash flow surged 120.9% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+83.1%
$28.5M→$52.1M

Strong top-line growth of 83.1% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+42.9%
$24.4M→$34.8M

Current liabilities surged 42.9% — significant near-term obligations; verify ability to meet short-term debt.

R&D Expense
P&L
-40.5%
$2.9M→$1.7M

R&D spending cut 40.5% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
+23.2%
$221.3M→$272.7M

Asset base grew 23.2% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+21.1%
$139.4M→$168.7M

Liabilities increased 21.1% — monitor debt-to-equity ratio and interest coverage.

Cash & Equivalents
Balance Sheet
-18.4%
$101.7M→$82.9M

Cash decreased 18.4% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-17
ADDED
Broadridge Broadridge Corporate Issuer Solutions, LLC BVF Biotechnology Value Fund, L.P.
Cash-Out Agreement Cash-Out Agreement between the Company and Thomas M.
Burns dated October 22, 2025 cGMP current Good Manufacturing Practice Company XOMA Royalty Corporation (formerly XOMA Corporation), including its subsidiaries DoD U.S.
Food and Drug Administration FDCA The Federal Food, Drug, and Cosmetic Act, as amended FDIC Federal Deposit Insurance Corporation GAAP Generally accepted accounting principles G A General and administrative HCRP Healthcare Royalty Partners II, L.P.
Wainwright Co., LLC IP Intellectual Property IPR D In-Process Research and Development IRA Inflation Reduction Act Leerink Leerink Partners LLC MAA Marketing Authorization Application NDA New Drug Application NOL Net operating loss PSU Performance stock unit R D Research and development Regeneron Regeneron Pharmaceuticals, Inc.
+7 more — sign up free →
REMOVED
Riley dated August 5, 2021 40 Act Investment Company Act of 1940 AAA Assignment and Assumption Agreement ACA The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 Affitech Affitech Research AS Affitech CPPA The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021 Agenus Agenus, Inc.
and certain affiliates Agenus RPA The Company's Royalty Purchase Agreement with Agenus dated September 20, 2018 Alora Alora Pharmaceuticals Alexion Alexion Pharmaceuticals Alexion License Agreement Exclusive License Agreement between the Company and Alexion (formerly Amolyt Pharma SAS, Amolyt ) dated December 19, 2024 Aptevo Aptevo Therapeutics Inc.
cGMP current Good Manufacturing Practice Chiesi Chiesi Farmaceutici S.p.A.
Company XOMA Royalty Corporation (formerly XOMA Corporation), including its subsidiaries CPPA Commercial Payment Purchase Agreement CVR Contingent value right Dar Organon License Agreement Exclusive License Agreement between Dar and Organon, dated March 31, 2022, as amended July 4, 2023 Dar RPAs The Company s Traditional Royalty Purchase Agreement and Synthetic Royalty Purchase Agreement, both with Dar dated April 29, 2024 Day One Day One Biopharmaceuticals, Inc.
Department of Defense EC European Commission EIR Effective interest rate EMA European Medicines Agency ESPP 2015 Employee Stock Purchase Plan, as amended EU European Union Exchange Act U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →